HomeCompareRYTTF vs MRK

RYTTF vs MRK: Dividend Comparison 2026

RYTTF yields 376.51% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RYTTF wins by $7369.57M in total portfolio value
10 years
RYTTF
RYTTF
● Live price
376.51%
Share price
$0.53
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7369.63M
Annual income
$4,840,554,618.52
Full RYTTF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — RYTTF vs MRK

📍 RYTTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRYTTFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RYTTF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RYTTF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RYTTF
Annual income on $10K today (after 15% tax)
$32,003.01/yr
After 10yr DRIP, annual income (after tax)
$4,114,471,425.74/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, RYTTF beats the other by $4,114,463,097.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RYTTF + MRK for your $10,000?

RYTTF: 50%MRK: 50%
100% MRK50/50100% RYTTF
Portfolio after 10yr
$3684.84M
Annual income
$2,420,282,208.33/yr
Blended yield
65.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

RYTTF
No analyst data
Altman Z
-0.1
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RYTTF buys
0
MRK buys
0
No recent congressional trades found for RYTTF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRYTTFMRK
Forward yield376.51%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$7369.63M$56.8K
Annual income after 10y$4,840,554,618.52$9,798.13
Total dividends collected$7132.95M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RYTTF vs MRK ($10,000, DRIP)

YearRYTTF PortfolioRYTTF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$48,351$37,650.60$11,206$366.19+$37.1KRYTTF
2$221,869$170,133.58$12,650$502.35+$209.2KRYTTF
3$967,026$729,626.27$14,407$694.19+$952.6KRYTTF
4$4,006,785$2,972,067.43$16,585$967.82+$3.99MRYTTF
5$15,796,135$11,508,874.72$19,342$1,363.89+$15.78MRYTTF
6$59,305,576$42,403,711.37$22,913$1,947.19+$59.28MRYTTF
7$212,243,898$148,786,931.74$27,662$2,823.89+$212.22MRYTTF
8$724,747,177$497,646,206.36$34,159$4,173.35+$724.71MRYTTF
9$2,363,617,489$1,588,138,009.63$43,337$6,308.80+$2363.57MRYTTF
10$7,369,625,331$4,840,554,618.52$56,776$9,798.13+$7369.57MRYTTF

RYTTF vs MRK: Complete Analysis 2026

RYTTFStock

Royalty North Partners Ltd. provides loan and royalty financing to private businesses. The company was formerly known as Bluefire Mining Corp. and changed its name to Royalty North Partners Ltd. in February 2016. Royalty North Partners Ltd. was incorporated in 2011 and is headquartered in Vancouver, Canada.

Full RYTTF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this RYTTF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RYTTF vs SCHDRYTTF vs JEPIRYTTF vs ORYTTF vs KORYTTF vs MAINRYTTF vs JNJRYTTF vs ABBVRYTTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.